Literature DB >> 29180699

Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence.

Sevin Turcan1,2, Vladimir Makarov3, Julian Taranda4, Yuxiang Wang3, Armida W M Fabius3,5, Wei Wu3, Yupeng Zheng6, Nour El-Amine4, Sara Haddock3,7, Gouri Nanjangud8, H Carl LeKaye9, Cameron Brennan10, Justin Cross11, Jason T Huse3, Neil L Kelleher12, Pavel Osten4, Craig B Thompson13, Timothy A Chan14,15,16.   

Abstract

Mutations in IDH1 and IDH2 (encoding isocitrate dehydrogenase 1 and 2) drive the development of gliomas and other human malignancies. Mutant IDH1 induces epigenetic changes that promote tumorigenesis, but the scale and reversibility of these changes are unknown. Here, using human astrocyte and glioma tumorsphere systems, we generate a large-scale atlas of mutant-IDH1-induced epigenomic reprogramming. We characterize the reversibility of the alterations in DNA methylation, the histone landscape, and transcriptional reprogramming that occur following IDH1 mutation. We discover genome-wide coordinate changes in the localization and intensity of multiple histone marks and chromatin states. Mutant IDH1 establishes a CD24+ population with a proliferative advantage and stem-like transcriptional features. Strikingly, prolonged exposure to mutant IDH1 results in irreversible genomic and epigenetic alterations. Together, these observations provide unprecedented high-resolution molecular portraits of mutant-IDH1-dependent epigenomic reprogramming. These findings have substantial implications for understanding of mutant IDH function and for optimizing therapeutic approaches to targeting IDH-mutant tumors.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29180699      PMCID: PMC5769471          DOI: 10.1038/s41588-017-0001-z

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  58 in total

1.  Targeting cancer stem cells through L1CAM suppresses glioma growth.

Authors:  Shideng Bao; Qiulian Wu; Zhizhong Li; Sith Sathornsumetee; Hui Wang; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

2.  IDH mutation impairs histone demethylation and results in a block to cell differentiation.

Authors:  Chao Lu; Patrick S Ward; Gurpreet S Kapoor; Dan Rohle; Sevin Turcan; Omar Abdel-Wahab; Christopher R Edwards; Raya Khanin; Maria E Figueroa; Ari Melnick; Kathryn E Wellen; Donald M O'Rourke; Shelley L Berger; Timothy A Chan; Ross L Levine; Ingo K Mellinghoff; Craig B Thompson
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

3.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

4.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

5.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

6.  Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.

Authors:  Kensuke Tateishi; Hiroaki Wakimoto; A John Iafrate; Shota Tanaka; Franziska Loebel; Nina Lelic; Dmitri Wiederschain; Olivier Bedel; Gejing Deng; Bailin Zhang; Timothy He; Xu Shi; Robert E Gerszten; Yiyun Zhang; Jing-Ruey J Yeh; William T Curry; Dan Zhao; Sudhandra Sundaram; Fares Nigim; Mara V A Koerner; Quan Ho; David E Fisher; Elisabeth M Roider; Lajos V Kemeny; Yardena Samuels; Keith T Flaherty; Tracy T Batchelor; Andrew S Chi; Daniel P Cahill
Journal:  Cancer Cell       Date:  2015-12-14       Impact factor: 31.743

7.  A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.

Authors:  Christopher G Duncan; Benjamin G Barwick; Genglin Jin; Carlo Rago; Priya Kapoor-Vazirani; Doris R Powell; Jen-Tsan Chi; Darell D Bigner; Paula M Vertino; Hai Yan
Journal:  Genome Res       Date:  2012-08-16       Impact factor: 9.043

8.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.

Authors:  Sevin Turcan; Daniel Rohle; Anuj Goenka; Logan A Walsh; Fang Fang; Emrullah Yilmaz; Carl Campos; Armida W M Fabius; Chao Lu; Patrick S Ward; Craig B Thompson; Andrew Kaufman; Olga Guryanova; Ross Levine; Adriana Heguy; Agnes Viale; Luc G T Morris; Jason T Huse; Ingo K Mellinghoff; Timothy A Chan
Journal:  Nature       Date:  2012-02-15       Impact factor: 69.504

9.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079

10.  Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile.

Authors:  François Ducray; Ahmed Idbaih; Aurélien de Reyniès; Ivan Bièche; Joëlle Thillet; Karima Mokhtari; Séverine Lair; Yannick Marie; Sophie Paris; Michel Vidaud; Khê Hoang-Xuan; Olivier Delattre; Jean-Yves Delattre; Marc Sanson
Journal:  Mol Cancer       Date:  2008-05-20       Impact factor: 27.401

View more
  60 in total

Review 1.  Chromatin dynamics underlying latent responses to xenobiotics.

Authors:  Jonathan Moggs; Rémi Terranova
Journal:  Toxicol Res (Camb)       Date:  2018-02-28       Impact factor: 3.524

2.  CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.

Authors:  Casey J Moure; Bill H Diplas; Lee H Chen; Rui Yang; Christopher J Pirozzi; Zhaohui Wang; Ivan Spasojevic; Matthew S Waitkus; Yiping He; Hai Yan
Journal:  Mol Cancer Res       Date:  2019-07-10       Impact factor: 5.852

3.  Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target.

Authors:  Candice D Carpenter; Iyad Alnahhas; Javier Gonzalez; Pierre Giglio; Vinay K Puduvalli
Journal:  Expert Rev Neurother       Date:  2019-05-27       Impact factor: 4.618

4.  A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level.

Authors:  Qi Liu; Kuanyu Wang; Ruoyu Huang; Xuezhi Tong; Tao Jiang; Jiangfei Wang; Pei Yang
Journal:  J Cancer Res Clin Oncol       Date:  2020-02-14       Impact factor: 4.553

5.  Biochemical and phylogenetic characterization of a monomeric isocitrate dehydrogenase from a marine methanogenic archaeon Methanococcoides methylutens.

Authors:  Peng Wang; Yuan Wang; Xiuxiu Guo; Shiping Huang; Guoping Zhu
Journal:  Extremophiles       Date:  2020-01-22       Impact factor: 2.395

Review 6.  Molecular Pathogenesis of Low-Grade Glioma.

Authors:  Devin Bready; Dimitris G Placantonakis
Journal:  Neurosurg Clin N Am       Date:  2019-01       Impact factor: 2.509

7.  Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia.

Authors:  Lucille Stuani; Marie Sabatier; Estelle Saland; Guillaume Cognet; Nathalie Poupin; Claudie Bosc; Florence A Castelli; Lara Gales; Evgenia Turtoi; Camille Montersino; Thomas Farge; Emeline Boet; Nicolas Broin; Clément Larrue; Natalia Baran; Madi Y Cissé; Marc Conti; Sylvain Loric; Tony Kaoma; Alexis Hucteau; Aliki Zavoriti; Ambrine Sahal; Pierre-Luc Mouchel; Mathilde Gotanègre; Cédric Cassan; Laurent Fernando; Feng Wang; Mohsen Hosseini; Emeline Chu-Van; Laurent Le Cam; Martin Carroll; Mary A Selak; Norbert Vey; Rémy Castellano; François Fenaille; Andrei Turtoi; Guillaume Cazals; Pierre Bories; Yves Gibon; Brandon Nicolay; Sébastien Ronseaux; Joseph R Marszalek; Koichi Takahashi; Courtney D DiNardo; Marina Konopleva; Véra Pancaldi; Yves Collette; Floriant Bellvert; Fabien Jourdan; Laetitia K Linares; Christian Récher; Jean-Charles Portais; Jean-Emmanuel Sarry
Journal:  J Exp Med       Date:  2021-05-03       Impact factor: 14.307

Review 8.  The implications of IDH mutations for cancer development and therapy.

Authors:  Christopher J Pirozzi; Hai Yan
Journal:  Nat Rev Clin Oncol       Date:  2021-06-15       Impact factor: 66.675

Review 9.  Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context.

Authors:  Junfeng Bi; Sihan Wu; Wenjing Zhang; Paul S Mischel
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-05-23       Impact factor: 10.680

Review 10.  DNA Repair Mechanisms and Therapeutic Targets in Glioma.

Authors:  Kevin B Elmore; Lauren R Schaff
Journal:  Curr Oncol Rep       Date:  2021-06-14       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.